PEG-MGF
Evidence: D+/C-GH Axis / Body Composition
Evidence Snapshot
What this grade covers
D+/C- is the overall page grade. Confidence in the regulatory/product-category identity context -- what PEG-MGF is understood to be, and FDA's own compounding-related statements about it -- is high, but that identity-level confidence does not by itself establish therapeutic efficacy. Related, non-pegylated MGF biology (endogenous transcript and synthetic E-peptide evidence) is preclinical and internally mixed, and does not constitute direct PEG-MGF efficacy evidence. Human exposure, efficacy, safety, muscle-growth, recovery, approval, and dosing evidence for PEG-MGF specifically remains extremely limited to absent, consistent with FDA's own statement that it has not identified human exposure data for PEG-MGF drug products.
Regulatory Context
PEG-MGF is not FDA approved. FDA identifies significant characterization, impurity, aggregation, immunogenicity, and missing-human-data concerns. WADA prohibits mechano growth factors in sport.
Research Takeaway
PEG-MGF is a pegylated form of a mechano-growth-factor peptide concept and is a distinct molecular entity from non-pegylated MGF/IGF-1Ec E-peptide.
Evidence boundary: MGF evidence cannot be assumed to describe PEG-MGF pharmacokinetics or safety.
See all 7 evidence claims →Quick Summary
PEG-MGF is a poorly standardized term for a pegylated synthetic peptide related to the mechano growth factor E-domain. It is not the same as endogenous IGF-1Ec, full-length MGF, ordinary IGF-1, or Long R3 IGF-I.
Mechanism & Research Overview
PEGylation can alter the disposition and immunologic properties of a peptide, but “PEG-MGF” is not a sufficient chemical identity without a defined peptide sequence, PEG size, attachment site, and formulation. MGF or PEG-IGF-I literature cannot be assumed to apply directly.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
PEG-MGF is a pegylated form of a mechano-growth-factor peptide concept and is a distinct molecular entity from non-pegylated MGF/IGF-1Ec E-peptide.
Does not establish
Evidence boundary: MGF evidence cannot be assumed to describe PEG-MGF pharmacokinetics or safety.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; Meeting of the Pharmacy Compounding Advisory Committee
Supported
FDA states that it has not identified human exposure data for drug products containing PEG-MGF.
Does not establish
Evidence boundary: Absence of identified human exposure data means human efficacy must not be claimed.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
PEG-MGF is not an FDA-approved drug, and FDA has evaluated it in the 503A compounding context rather than as an approved therapeutic product.
Does not establish
Evidence boundary: Compounding-list consideration is not approval.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks; Meeting of the Pharmacy Compounding Advisory Committee; Tailor Made Compounding LLC - Warning Letter
Supported
FDA identifies potential significant immunogenicity risk, peptide-related impurity concerns, and API-characterization complexity for compounded PEG-MGF.
Does not establish
Evidence boundary: These concerns do not quantify incidence because adequate human safety data are lacking.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
No human efficacy claim for muscle growth, recovery, fat loss, or anti-aging is supportable from the frozen evidence package.
Does not establish
Evidence boundary: Preclinical or non-pegylated MGF evidence cannot fill the human PEG-MGF evidence gap.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
No human Study/Trial Dosing should be displayed because FDA reports no identified human exposure data; animal or laboratory exposure must remain explicitly preclinical and must not be converted into consumer guidance.
Does not establish
Evidence boundary: This rule forbids inferred human dosing from related MGF products.
Sources: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Supported
The three MGF-related weak study references on this page (study-mgf-matheny-2010-review, study-mgf-kandalla-2011, study-mgf-fornaro-2014) were investigated during Batch 10 reconciliation and confirmed to be legitimate weak references to real, verified study records that currently exist only as unpublished drafts -- consistent with this project's established weak-reference-to-unpublished-base-ID convention -- not invalid, broken, or fabricated citations.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Possible proliferative, angiogenic, or tumor-related signaling; unknown cardiac, hepatic, renal, reproductive, neurologic, and developmental effects; unknown interaction with insulin, GH, IGF-1, anabolic steroids, cancer, or diabetes; and absence of adequate repeated-dose, pregnancy, pediatric, or long-term data.Safety Consideration
Possible IGF-1 receptor or IGF-axis activity depending on construct; hypoglycemia or glucose dysregulation are unaddressed possibilities.Safety Consideration
The catalog does not specify peptide sequence, PEG molecular weight, conjugation site, or formulation.Safety Consideration
No peer-reviewed human administration study for a standardized PEG-MGF product was verified in this audit.Safety Consideration
Potential risks cannot be characterized without a defined substance and direct evidence.Safety Consideration
MGF, IGF-1, PEG-IGF-I, and other PEGylated proteins are not substitutes for direct PEG-MGF evidence.Safety Consideration
Unspecified PEGylated products may carry identity, impurity, immunogenicity, and sterility risks.Safety Consideration
Anti-PEG antibodies, complement activation or hypersensitivity, and altered clearance are unaddressed by the current evidence base.Safety Consideration
PEGylation may prolong exposure or alter distribution, but it does not automatically improve safety, selectivity, or effectiveness. Edema, fluid retention, arthralgia, and soft-tissue effects are noted by analogy only and are not established PEG-MGF event rates.
Research Areas Being Studied
Research areas discussed on this page reflect the GH Axis / Body Composition category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Producing Human Mechano Growth Factor in E. coli | Recombinant full-length MGF has been produced and tested in laboratory systems. Full-length recombinant protein is not equivalent to pegylated E-domain peptide. | ||||
| Synthetic MGF E-Domain Peptide and Human Myogenic Precursor Migration | Cell and animal studies of unpegylated MGF-related peptides have reported effects on myogenic precursor proliferation or migration. These are not studies of a defined commercial PEG-MGF product. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | 2026 | FDA states that compounded PEG-MGF may pose significant immunogenicity and impurity/API-characterization risks and that it has not identified human exposure data for PEG-MGF drug products. FDA also lists safety concerns for compounded Melanotan II. | |||
| Meeting of the Pharmacy Compounding Advisory Committee | 2026 | FDA listed PEG-MGF and Melanotan II among bulk drug substances considered for the 503A Bulks List. Committee consideration is not approval. | |||
| Tailor Made Compounding LLC - Warning Letter | 2020 | FDA identified compounded IGF1-LR3, Cerebrolysin, PEG-MGF, and Melanotan II products that did not qualify for cited section 503A exemptions and were not components of FDA-approved human drugs. | |||
| WADA Research on Analytical Detection of MGF Analogues | WADA-sponsored analytical research on detection of MGF analogues speaks to anti-doping testing methodology, not to PEG-MGF's chemical identity, efficacy, or human safety. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
PEG-MGF remains an insufficiently characterized research label with no verified human evidence base. This draft is for internal research organization only and is not medical advice.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for PEG-MGF
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.